Close Menu
    Stocks

    Johnson & Johnson (JNJ) Stock Climbs Following Strong Q1 2026 Financial Results

    Oli DaleBy No Comments4 Mins Read

    Key Takeaways

    • Johnson & Johnson delivered Q1 adjusted earnings of $2.70 per share, surpassing the Street’s $2.68 projection, while revenue reached $24.1 billion versus $23.6 billion anticipated.
    • The pharmaceutical segment climbed 11.2% compared to the prior year, generating $15.4 billion, with standout contributions from Darzalex ($4.0B) and Tremfya ($1.6B).
    • Full-year 2026 revenue outlook was increased to $100.8 billion, while adjusted earnings per share guidance rose to $11.55.
    • According to Truist Securities, J&J’s newly approved psoriasis treatment Icotyde has the potential to achieve approximately $10 billion in peak annual sales.
    • Shares of JNJ have surged 15% so far in 2026, significantly outpacing the S&P 500’s 0.6-1% advance.

    Johnson & Johnson unveiled its first-quarter 2026 financial performance on Tuesday morning, delivering both revenue and profit figures that exceeded analyst projections.

    Revenue totaled $24.1 billion, representing a 10% increase from the corresponding quarter last year and topping the $23.6 billion consensus estimate compiled by FactSet. On an adjusted basis, the healthcare giant earned $2.70 per share, slightly beating the $2.68 forecast.

    Shares climbed approximately 1.2% during premarket hours after the announcement.


    JNJ Stock Card
    Johnson & Johnson, JNJ

    The quarter represents another milestone in J&J’s ongoing transformation. Over recent years, the corporation has pivoted away from consumer health offerings — divesting the Kenvue business, which Kimberly-Clark is now acquiring — to sharpen its focus on pharmaceutical innovations and medical technology.

    The pharmaceutical division stood out as the star performer, growing 11.2% year-over-year to reach $15.4 billion. This figure exceeded the FactSet consensus of $15.2 billion.

    Darzalex, the company’s leading multiple myeloma treatment, generated $4.0 billion in quarterly revenue, up from $3.2 billion in the year-ago period. Analysts had projected $3.9 billion.

    Tremfya, an IL-23 inhibitor prescribed for autoimmune disorders, recorded $1.6 billion in sales, climbing substantially from $956 million last year and comfortably surpassing the $1.4 billion estimate.

    Autoimmune Innovation Drives Growth

    Last September, the FDA greenlit Tremfya’s subcutaneous formulation for ulcerative colitis and Crohn’s disease patients, establishing it as the first medication in its class that patients can administer themselves at home. This convenience factor gives it a competitive edge over AbbVie’s Skyrizi, which necessitates clinic-based initial infusions.

    In the previous month, J&J secured FDA clearance for Icotyde, an innovative oral IL-23 inhibitor tablet for plaque psoriasis, stemming from a 2017 licensing agreement with Protagonist Therapeutics. Truist Securities analyst Srikripa Devarakonda projects Icotyde could ultimately generate approximately $10 billion in peak annual revenue. The company has not yet released any commercial sales data.

    The medical technology segment contributed $8.6 billion in revenue, matching analyst expectations.

    Net profit totaled $5.2 billion, falling short of the FactSet projection of $6.5 billion — marking the second straight quarter where bottom-line earnings missed forecasts.

    Updated Outlook and Ongoing Litigation

    For the complete 2026 fiscal year, J&J has revised its revenue forecast upward to $100.8 billion from the previous $100.5 billion target. Adjusted earnings per share guidance was similarly elevated to $11.55 from $11.03. Wall Street analysts had anticipated $11.54 per share and $100.6 billion in revenue.

    The corporation continues to face significant legal challenges. As of the conclusion of Q4 2025, J&J was defending against 74,360 lawsuits alleging it deliberately marketed talcum powder products contaminated with asbestos, a known carcinogen. Its latest effort to settle these claims via a bankruptcy filing through subsidiary Red River Talc was rejected by a Texas court, permitting individual legal actions to move forward.

    J&J maintains its position that the baby powder product, currently marketed under the Kenvue brand, is both safe and free of asbestos contamination.

    Among 29 analyst firms monitored by FactSet, 17 assign JNJ a Buy rating or equivalent recommendation. Two analysts rate it a Sell.

    JNJ stock has appreciated 15% year-to-date in 2026, substantially outperforming the S&P 500’s roughly 0.6% to 1% gain during the identical timeframe.

    Share.

    Related Posts

    Leave A Reply